Analyst Price Target Update on Organovo Holdings (NYSEMKT:ONVO)

Organovo Holdings (NYSEMKT:ONVO) stock has received a short term price target of $ 3.5 from 2 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $0.71. The higher estimate of target price is $4 , while the lower price target estimate is $3

For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Baltera Robert Jr., director of Organovo Holdings, Inc., had unloaded 6,000 shares at an average price of $4.03 in a transaction dated on September 21, 2015. The total value of the transaction was worth $24,180.

Organovo Holdings (NYSEMKT:ONVO) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.21 points or 6.77% at $2.89 with 970,567 shares getting traded. Post opening the session at $3.15, the shares hit an intraday low of $2.89 and an intraday high of $3.19 and the price was in this range throughout the day. The company has a market cap of $267 million and the number of outstanding shares have been calculated to be 92,391,989 shares. The 52-week high of Organovo Holdings (NYSEMKT:ONVO) is $5.65 and the 52-week low is $1.6.

Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *